Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, China; Department of Pathology and Pathophysiology, Southeast University School of Medicine, Nanjing, China.
Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, China.
J Control Release. 2022 Sep;349:32-50. doi: 10.1016/j.jconrel.2022.06.049. Epub 2022 Jul 4.
With the ever-increasing burden of kidney disease, the need for developing new therapeutics to manage this disease has never been greater. Extracellular vesicles (EVs) are natural membranous nanoparticles present in virtually all organisms. Given their excellent delivery capacity in the body, EVs have emerged as a frontier technology for drug delivery and have the potential to usher in a new era of nanomedicine for kidney disease. This review is focused on why EVs are such compelling drug carriers and how to release their fullest potentiality in renal therapeutics. We discuss the unique features of EVs compared to artificial nanoparticles and outline the engineering technologies and steps in developing EV-based therapeutics, with an emphasis on the emerging approaches to target renal cells and prolong kidney retention. We also explore the applications of EVs as natural therapeutics or as drug carriers in the treatment of renal disorders and present our views on the critical challenges in manufacturing EVs as next-generation renal therapeutics.
随着肾脏疾病负担的不断增加,开发新的治疗方法来治疗这种疾病的需求从未如此之大。细胞外囊泡(EVs)是几乎所有生物体中存在的天然膜性纳米颗粒。鉴于它们在体内具有出色的输送能力,EVs 已经成为药物输送的前沿技术,有可能为肾脏疾病带来纳米医学的新时代。本综述重点介绍了 EVs 为何是如此引人注目的药物载体,以及如何在肾脏治疗中释放它们的最大潜力。我们讨论了 EVs 与人工纳米颗粒相比的独特特征,并概述了开发基于 EV 的治疗方法的工程技术和步骤,重点介绍了针对肾脏细胞和延长肾脏保留的新兴方法。我们还探讨了 EVs 作为天然治疗剂或药物载体在治疗肾脏疾病中的应用,并就制造 EVs 作为下一代肾脏治疗剂的关键挑战提出了我们的看法。